BARD1 Life Sciences Ltd is an Australian medical diagnostics company that specialises in developing innovative diagnostic technologies and products for healthcare professionals and patients. The company's primary focus is on providing lifesaving diagnostic solutions for cancer, including bladder, ovarian, breast, lung, prostate, and pancreatic cancers. BARD1's portfolio includes the hTERT test, which is used to aid in the diagnosis of bladder cancer. The company is dedicated to improving the detection of cancer and developing more accurate and effective diagnostic tools.
Bard1's ticker is BD1
The company's shares trade on the ASX stock exchange
They are based in Notting Hill, Australia
There are 11-50 employees working at Bard1
It is https://www.bard1.com/
Bard1 is in the Healthcare sector